Nami Babak, Maadi Hamid, Wang Zhixiang
Signal Transduction Research Group, Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
Cancers (Basel). 2018 Sep 20;10(10):342. doi: 10.3390/cancers10100342.
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20⁻30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as adjuvant therapy in combination with docetaxel to treat metastatic HER2-positive breast cancer. Adding the monoclonal antibodies to treatment regimen has changed the paradigm for treatment of HER2-positive breast cancer. Despite improving outcomes, the percentage of the patients who benefit from the treatment is still low. Continued research and development of novel agents and strategies of drug combinations is needed. A thorough understanding of the molecular mechanisms underlying the action and synergism of trastuzumab and pertuzumab is essential for moving forward to achieve high efficacy in treating HER2-positive breast cancer. This review examined and analyzed findings and hypotheses regarding the action and synergism of trastuzumab and pertuzumab and proposed a model of synergism based on available information.
人表皮生长因子受体（HER）2（HER2）在20%-30%的乳腺癌中呈过表达。HER2是治疗HER2阳性乳腺癌的首选靶点。曲妥珠单抗和帕妥珠单抗是美国食品药品监督管理局（FDA）批准的两种HER2靶向单克隆抗体，可与多西他赛联合用作辅助治疗，以治疗转移性HER2阳性乳腺癌。在治疗方案中添加单克隆抗体改变了HER2阳性乳腺癌的治疗模式。尽管改善了治疗效果，但从该治疗中获益的患者比例仍然较低。仍需要继续研发新型药物和药物联合策略。深入了解曲妥珠单抗和帕妥珠单抗作用及协同作用的分子机制，对于在治疗HER2阳性乳腺癌中实现高效治疗至关重要。本综述研究并分析了关于曲妥珠单抗和帕妥珠单抗作用及协同作用的研究结果和假说，并根据现有信息提出了一种协同作用模型。
Zotero 插件
